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Abstract
Background: Although causing substantial morbidity, the burden of pneumococcal disease among older children and 
adults in Africa, particularly in rural settings, is not well-characterized. We evaluated pneumococcal bacteremia among 
21,000 persons ≥5 years old in a prospective cohort as part of population-based infectious disease surveillance in rural 
western Kenya from October 2006-September 2008.
Methods: Blood cultures were done on patients meeting pre-defined criteria - severe acute respiratory illness (SARI), 
fever, and admission for any reason at a referral health facility within 5 kilometers of all 33 villages where surveillance 
took place. Serotyping of Streptococcus pneumoniae was done by latex agglutination and quellung reaction and 
antibiotic susceptibility testing was done using broth microdilution. We extrapolated incidence rates based on persons 
with compatible illnesses in the surveillance population who were not cultured. We estimated rates among HIV-
infected persons based on community HIV prevalence. We projected the national burden of pneumococcal 
bacteremia cases based on these rates.
Results: Among 1,301 blood cultures among persons ≥5 years, 52 (4%) yielded pneumococcus, which was the most 
common bacteria isolated. The yield was higher among those ≥18 years than 5-17 years (6.9% versus 1.6%, p < 0.001). 
The highest yield was for inpatients with SARI (10%), compared with SARI outpatients (3%) and acute febrile 
outpatients (1%). Serotype 1 pneumococcus was most common (42% isolates) and 71% were serotypes included in 
the 10-valent pneumococcal conjugate vaccine (PCV10). Non-susceptibility to beta-lactam antibiotics was low (<5%), 
but to trimethoprim-sulfamethoxazole was high (>95%). The crude rate of pneumococcal bacteremia was 129/100,000 
person-years, and the adjusted rate was 419/100,000 person-years. Nineteen (61%) of 31 patients with HIV results were 
HIV-positive. The adjusted rate among HIV-infected persons was 2,399/100,000 person-years (Rate ratio versus HIV-
negative adults, 19.7, 95% CI 12.4-31.1). We project 58,483 cases of pneumococcal bacteremia will occur in Kenyan 
adults in 2010.
Conclusions: Pneumococcal bacteremia rates were high among persons ≥5 years old, particularly among HIV-infected 
persons. Ongoing surveillance will document if expanded use of highly-active antiretroviral treatment for HIV and 
introduction of PCV10 for Kenyan children (anticipated in late 2010) result in substantial secondary benefits by 
reducing pneumococcal disease in adults.
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Background
The burden of disease caused by Streptococcus pneumo-
niae (pneumococcus) in young African children is well-
established [1-3]. A recent analysis estimated over 4 mil-
lion cases and almost a half-million deaths from pneumo-
coccal disease occur among African children < 5 years old
annually [3]. The burden of pneumococcal disease in
older children and adults in Africa, particularly in rural
settings, is less well-characterized, although is likely sub-
stantial. Several studies in Africa have shown pneumo-
coccus to be one of the principal causes of severe
bacterial bloodstream infections in hospitalized adults,
along with Mycobacterium tuberculosis and non-typhi
salmonellae [4-11].
Few studies have assessed rates of pneumococcal dis-
ease because of lack of well-defined denominators in
most African settings [6,7,12-15]. Moreover, no studies
have adjusted rates based on health-seeking patterns
among adults in Africa, where many sick adults do not
attend health facilities. Better understanding of adult
pneumococcal burden and epidemiology in African
adults, including the serotype distribution and contribut-
ing role of HIV disease, will help predict, target and eval-
uate preventive strategies. We evaluated two years of
population-based surveillance from rural western Kenya
to better define the epidemiology and burden of pneumo-
coccal bacteremia among older children and adults, and
identify epidemiological factors that could potentially
decrease this burden.
Methods
Site
CDC's International Emerging Infections Program and
the Kenya Medical Research Institute (KEMRI) have con-
ducted population-based, morbidity surveillance since
late 2005 in Asembo in rural western Kenya. The surveil-
lance population on July 1, 2007 included 21,420 persons
≥5 years old living in approximately 6,000 households. All
participants who resided permanently in the area for 4
calendar months and had been registered in the KEMRI/
CDC Demographic Surveillance System were eligible for
participation in surveillance [16,17]. Malaria transmis-
sion is endemic, occurring year-round, with approxi-
mately 50% of sick children and 15% of sick adults having
malaria positive blood smears in 2006-2008 [16]. The
inhabitants are poor with over 66% of individuals living
below the poverty line [18].
Surveillance methods
All 33 enrolled villages are within 5 kilometers of the
referral facility, Lwak Mission Hospital, which has both
outpatient and inpatient capacity. Study participants
receive free medical care at Lwak for most acute condi-
tions, including all possible infectious diseases. Patients
are examined and diagnosed by study-trained clinical
officers (similar to physician's assistants). As part of sur-
veillance, blood cultures are done on enrolled persons ≥5
years meeting one of three case definitions.
1. Severe acute respiratory illness (SARI), defined as 
cough or difficulty breathing and either temperature 
≥38.0°C or oxygen saturation < 90% (all patients).
2. Acute febrile illness, defined as a temperature 
≥38.0°C, without SARI or other obvious source (e.g. 
bloody diarrhea), irrespective of malaria blood smear 
result (first two patients per day regardless of severity 
or diagnosis).
3. All patients admitted for conditions unrelated to 
injury or obstetrics.
Scannable paper questionnaires are completed on all
sick visits at Lwak, documenting symptoms, health-seek-
ing, physical exam, diagnosis, treatment and outcome
(TeleForm®, Cardiff™, California).
Three other Ministry of Health outpatient health facili-
ties are in or near the surveillance area. Blood cultures are
not done at these facilities and no data is collected on vis-
its to these facilities on participants of the surveillance
population. No private clinics are in the area. HIV care
was available in Lwak and one other area clinic during
this time (one day per week); however, in 2008 only
approximately 26% and 17% of HIV-infected persons
were taking cotrimoxazole prophylaxis and highly active
antiretroviral therapy (KEMRI/CDC data).
Community interviewers visit enrolled households
every two weeks to inquire about illnesses [17]. Symp-
toms are recorded and an abbreviated physical exam is
done by trained field workers. Participants are asked if
and where they sought health care. Using household visit
data, we defined SARI as an episode with cough or diffi-
culty breathing and reported fever and defined acute
febrile illness as someone with reported fever without
cough, difficulty breathing, or bloody diarrhea.
Laboratory
Blood collected for culture was inoculated into commer-
cially-produced blood culture bottles (BACTEC™ Aerobic
PLUS™, Becton Dickinson, Belgium). Seven-to-ten ml of
blood was inoculated in bottles, which remained at room
temperature (approximately 30°C) for 2-6 hours before
being incubated in an automated BACTEC 9050 for 4
days. Blood from bottles signaling a positive culture was
gram-stained and sub-plated onto standard media for
bacteria identification using routine microbiologic tech-
niques [19,20]. Streptococcus pneumoniae was identified
by colony morphology, optochin susceptibility and bile
solubility. Isolates were stored at -70°C in 20% glycerol
broth. Antimicrobial susceptibility patterns were deter-
mined using broth microdilution at the CDC Streptococ-
cus laboratory (Atlanta, US), and minimum inhibitoryFeikin et al. BMC Infectious Diseases 2010, 10:186
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concentrations for nonmeningitis breakpoints were used
according to standard interpretative criteria [19]. Sero-
typing was performed using latex agglutination and quel-
lung reaction by KEMRI/Wellcome Trust in Kilifi, Kenya
(typing sera and reagents purchased from Statens Serum
Institut, Copenhagen, Denmark) or the CDC Streptococ-
cus laboratory (CDC typing sera and reagents).
HIV testing was performed as part of a home-based
testing initiative in 2008 in which all persons ≥13 years in
the surveillance area were offered HIV testing. Approxi-
mately 79% of eligible persons agreed to have an HIV test
or reveal previously positive results (10,197 of 12,906 eli-
gible, KEMRI/CDC data). Eligible persons were adminis-
tered two parallel HIV rapid tests (Determine™, Abbott
Laboratories, USA) and Bioline™ (Standard Diagnostics,
Kyonggi-do, Korea) by trained counselors, with a tie-
breaker test for discordant results (Uni-gold™, Trinity
Biotech, Ireland). We assumed that a person's HIV status
during home-based testing was the same throughout the
study period. Participants without available HIV results
had refused, had out-migrated, or had died before the
home-based testing initiative. We did not do HIV-testing
in the clinic on most patients during this period.
Data analysis
Clinic visits, household visits, and laboratory test results,
including HIV, were linked by common ID numbers. Data
analyses were performed using SAS (version 9.1). Differ-
ences in proportions were assessed by chi-square tests
and means by t-tests. Crude rates were calculated as the
number of cases of pneumococcal bacteremia per
100,000 person-years. Each participating individual con-
tributed person-time according to their dates of residence
within the Demographic Surveillance System from Octo-
ber 1, 2006 - September 30, 2008 [16]. 95% confidence
intervals were calculated for crude rates using Fisher's
method (Computer Programs for Epidemiologists, PEPI,
version 4.0x) and for extrapolated rates using the delta
method [21].
Two adjustments were applied on crude rates. First, a
multiplier was included for the percentage of persons vis-
iting Lwak Hospital who met a criterion for blood culture
and did not have a culture done. The reasons for not get-
ting cultured included the clinician not recognizing that
the patient met the case definition, the patient refusing
the blood draw, febrile patients presenting after two
febrile persons had already been sampled that day, or an
inpatient having already received intravenous antibiotics
before blood for culture could be taken. The percentage
of uncultured patients was obtained separately for 4 age
categories and for each indication for blood culturing. A
second adjustment was made based on the percentage of
persons identified with each of the indications for blood
culture at the household visit who visited a clinic other
than Lwak for that illness. W e assumed that those who
visited another clinic had a comparable severity and spec-
trum of etiologies to those that visited Lwak for the same
syndrome.
To estimate the pneumococcal bacteremia rate in HIV-
infected persons, we calculated the numerator by apply-
ing the same proportion of HIV-positivity among
patients with pneumococcal bacteremia in whom HIV
status was known to those whom the HIV status was
unknown. Population prevalence of HIV by age group
was obtained from the home-based HIV testing initiative
in the surveillance population The HIV prevalence
among 18-34 year olds was 19%, among 35-49 year olds
was 28%, and among those ≥50 years was 6%. HIV preva-
lence rates were applied to the person-time calculated for
each age category to obtain the person-years denomina-
tor for adults with and without HIV. Children and adoles-
cents aged 5-17 years were excluded from the HIV-
s pec i f i c  r a t e  c a l c u l a t i o n s  a s  t h ey  w e r e  n o t  c o n s i s t e n t l y
included in home-based HIV testing so denominator
populations were not calculable. Rate ratios between
HIV-positive and -negative individuals were calculated
using Breslow's test for 95% confidence intervals.
We projected the number of pneumococcal bactere-
mias among persons ≥18 years old in Kenya in 2010. We
used the extrapolated rates of pneumococcal bacteremia
among HIV-positive and HIV-negative persons, the 2010
projected age- and sex-specific population of Kenya, and
the age- and sex-specific HIV prevalence among all
Kenyans from the 2007 Kenya AIDS Indicator Survey
(KAIS) [22,23]. Because KAIS did not do HIV-testing on
persons ≥65 years old, we assumed that all persons ≥65
years were HIV-negative for purposes of the projection.
Ethical review
The protocol and written informed consent forms for
both surveillance and home-based HIV testing were
reviewed and approved by the Ethical Review Board of
KEMRI and the Institutional Review Board of CDC.
Results
During the study period, 16,322 patients ≥5 years visited
Lwak Hospital -- 15,078 (92%) outpatients and 1,244 (8%)
inpatients. Of these, 1,301 (8%) had blood cultures done,
which was 47% of those meeting the indications for blood
culture. Among the 1,301 cultures, 89 (6.8%) yielded true
pathogens (excluding 33 contaminants, 2.5% of total cul-
tures). Eight (0.6%) bottles were BACTEC alarm-positive,
but culture-negative. A reported history of prior antibi-
otic use for the current illness did not decrease the recov-
ery of pathogens (9% with antibiotic use versus 6%
without, p = 0.25). Streptococcus pneumoniae was the
most common bacterial isolate, recovered in 52 blood
cultures among 51 patients, accounting for 58% of allFeikin et al. BMC Infectious Diseases 2010, 10:186
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Page 4 of 9
pathogens and 4% of all blood cultures. (One patient had
bacteremia with serotype 6B pneumococcus in February
and August 2007.) Nontyphi Salmonella  group B
accounted for 15 (17%) isolates, Salmonella Typhi for 9
(10%) and Staphylococcus aureus for 8 (9%). The remain-
ing isolates included two Escherichia coli, and one each of
nontypable  Haemophilus influenzae, Group B strepto-
coccus, and Klebsiella pneumoniae.
The median age of the 51 patients with pneumococcal
bacteremia was 30 years (IQR 23-47); 11 (22%) were 5-17
years (Table 1). Children, 5-17 years were less likely than
persons ≥18 years to have pneumococcal bacteremia
(1.6% versus 6.9% of cultures, p < 0.001), and less likely to
be infected with HIV (11% versus 82%, p < 0.001). Overall
there was no difference by sex (52% female). Two patients
(4%) had concomitant malaria parasitemia.
The majority (52%) of all pneumococcal bacteremias
were among patients hospitalized with SARI. (Table 2).
Likewise, the highest pneumococcal isolation rate from
blood cultures was among patients admitted with SARI
(10%), compared with 3% for SARI outpatients and for
non-SARI admissions (Table 2). Of note, 6 of 9 admitted
non-SARI inpatients had a cough or difficulty breathing,
although not meeting the SARI definition due to lack of
fever or low oxygen saturation. Using household surveil-
lance da ta, four (7.7%) pa tients died wit hin 30 da ys of
their pneumococcal bacteremic episode, while another 3
(5.8%) died within the following 6 months (at days 30, 75
and 141).
Among the 17 serotypes identified, serotype 1
accounted for 42%, followed by serotypes 6B and 15A (8%
each, Table 3). Thirteen (25%) isolates were serotypes in
the 7-valent pneumococcal conjugate vaccine (PCV7)
and 37 (71%) were in the 10-valent conjugate vaccine
(PCV10). Serotype 1 was more common among younger
patients (82% among 5-17 year olds versus 32% among
persons ≥18 years, p = 0.005), but did not vary by sex
(Table 1). Among patients ≥18 years old with HIV status
available, serotype 1 tended to be less common among
HIV-positive patients (2/18, 11%) compared with HIV-
negative patients (2/4, 50%, p = 0.13). The percentage of
serotypes in PCV10 was lower among HIV-positive per-
sons (12/19, 63%) than among HIV-negative persons (12/
12,100%), p = 0.026).
There was no clear seasonal pattern to pneumococcal
disease, nor did there appear to be temporal or spatial
clustering of serotype 1 cases (Figure 1). There were no
differences in syndrome when comparing serotype 1 to
other serotypes (76% versus 81% were from SARI
patients, respectively, p = 0.70). Among patients infected
with serotype 1 pneumococci, 62% were hospitalized and
9.5% died, which was similar to those infected with other
serotypes, where 74% were hospitalized and 6.5% died (p
= NS).
Among 51 isolates with MIC testing, intermediate
resistance was found among 1 (2%) isolate for parenteral
penicillin, 2 (4%) isolates for amoxicillin and 1 (2%) iso-
late for cefotaxime; no full resistance to beta-lactams was
found. Trimethoprim-sulfamethoxazole nonsusceptibil-
ity was high - 45 (88%) isolates were resistant and 4 (8%)
were intermediate. Only 1 (2%) isolate was resistant to
chloramphenicol and 1 (2%) other isolate was resistant to
clindamycin and erythromycin. No isolates were nonsus-
ceptible to levofloxacin.
The overall crude rate of pneumococcal bacteremia in
persons ≥5 years was 129 cases per 100,000 person-years;
the overall adjusted rate was 419 per 100,000 person-
years (Table 4). Rates were highest among 18-49 year
olds. As a comparison with adult bacteremia rates, during
the same time period five pneumococcal isolates were
Table 1: Bacteremia by age group among persons ≥5 years of age presenting to Lwak Hospital, rural western Kenya, 
October 2006 - September 2008
Age in years 5-17 18-34 35-49 ≥50 Total
Number patients 7683 3678 2375 2586 16322
Number blood cultures (% patients) 703 (9.2 ) 275 (7.5 ) 186 (7.8) 137( 5.3) 1301 (8.0 )
Positive blood cultures (% of cultures)a 21 (3.0) 33 (12.0) 22 (11.8) 13 (9.5) 89 (6.8)
Pneumococcus recovered (% of cultures) 11 (1.6) 22 (8.0) 10 (5.4) 9 (6.6) 52 (4.0)
Serotype 1 (% of pneumococci) 9 (81.8) 6 (27.3) 3 (30.0) 4 (44.4) 22 (42.3)
HIV positive/number tested (%) 1/9 (11.1) 12/13 (92.3) 4/5 (80.0) 2/4 (50.0) 19/31 (61.3)
aExcludes contaminants.Feikin et al. BMC Infectious Diseases 2010, 10:186
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recovered in children aged < 5 years in 6,932 person-
years, yielding a crude incidence rate of 72 per 100,000
person-years with an adjusted rate of 203 per 100,000
person-years. The extrapolated rate of pneumococcal
bacteremia among HIV-infected persons ≥18 years in the
surveillance population was 2,399 per 100,000 person-
years, compared with 122 per 100,000 person-years in
HIV-negative persons ≥18 years old (Rate ratio 19.7, 95%
CI 12.4-31.1). Extrapolating these rates to the Kenya pop-
ulation, we project that in 2010 there will be 58,483 cases
of pneumococcal bacteremia among persons ≥18 years
old in Kenya, 34,872 among HIV-positive and 23,611
among HIV-negative persons.
Discussion
Like most studies of bacteremia in older children and
adults in Africa, pneumococcus was the most common
pathogen identified, accounting for 58% of isolates [1,4-
9]. Because our study was population-based with active
surveillance in the community, we could adjust crude
rates to better assess actual rates of pneumococcal bacte-
r e m i a,  w h i c h  w a s  a l m o s t  d o u b l e  t h a t  m e a s u r ed  i n  t h e
clinic. Moreover, home-based HIV testing in the commu-
nity allowed calculation of rates of pneumococcal bacter-
emia in HIV-infected persons, which showed that almost
one in four HIV-infected adults likely suffer pneumococ-
cal bacteremia each year. The extrapolated rate of pneu-
mococcal bacteremia among HIV-positive persons in our
population (2,399 per 100,000 person-years) rivaled the
crude rates among prospective cohorts of South African
miners (2,136 per 100,000 person-years) and HIV-
infected commercial sex workers in Nairobi (2,380 per
100,000 person-years) and HIV-infected adults in a trial
of pneumococcal polysaccharide vaccine in Uganda
(1,200 per 100,000 person-years), and was higher than the
crude rate observed in urban South Africa (197 per
100,000 persons) [6,12-14]. In rural western Kenya, HIV
infection seems to drive the high overall rate of pneumo-
coccal bacteremia among adults, being 19.7 times more
common among HIV-positive than HIV-negative adults;
this elevated rate ratio is similar to South Africa (rate
ratios of 6-55) and urban Kenya (rate ratio 17.8) [6,7,13-
15].
The majority (79%) of pneumococcal bacteremic epi-
sodes occurred in patients with SARI with a predomi-
nance among those hospitalized. Only 5 (10%) of
pneumococcal bacteremia patients did not report any
respiratory symptoms. However, culturing only hospital-
ized patients would have missed 31% of pneumococcal
bacteremia. Studies of invasive pneumococcal disease in
Africa have yielded case-fatality proportions averaging
14-16%; the lower case-fatality proportion we found
(7.7%) likely results from inclusion of outpatients, as well
as not collecting cerebrospinal fluid on higher mortality
meningitis cases [6,7,9,12,14,24]. The serotype distribu-
tion in western Kenyan is similar to that found in other
Table 2: Bacteremia by clinical syndrome among persons ≥5 years of age presenting to Lwak Hospital, rural western Kenya , 
October 2006 - September 2008
SARIa - Not Admitted SARI - Admitted Admitted -- not SARI Fever Only (temp >= 38.0) Total
Number patients (N) 1030 418 822 481 2751
Number blood cultures (% 
clinic visits)
514 (49.9) 264 (63.2) 315 (38.3) 190 (39.5) 1283b (46.6)
Positive blood cultures (% 
of cultures)c
25 (4.9) 41 (15.5) 18 (5.7) 4 (2.1) 88 (6.9)
Pneumococcus recovered 
(% of cultures)
14 (2.7) 27 (10.2) 9 (2.9) 2 (1.1) 52 (4.1)
Serotype 1 (% 
pneumococci)
6 (42.9) 11 (40.7) 3 (33.3) 2 (100) 22 (42.3)
HIV positive/number 
tested (%)
5/9 (55.6) 9/13 (69.2) 5/7 (71.4) 0/2 (0) 19/31(61.3)
aSARI is severe acute respiratory illness (see methods).
b18 patients were cultured for other reasons besides the 4 criteria listed.
cExcludes contaminants.Feikin et al. BMC Infectious Diseases 2010, 10:186
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adult populations in Africa [14,24-31]. Serotype 1 is uni-
formly the most common serotype found among African
adults, ranging from 18-36% [28]. Serotype 1 predomi-
nated in large outbreaks of pneumococcal disease in the
pre-antibiotic era and has more recently caused out-
breaks of meningitis in West Africa [32,33]. We did not
find evidence for serotype 1 outbreaks in our population
as no tem poral or spa tial clust ering of cases occurred.
The increased prevalence of serotype 1 in HIV-negative
compared with HIV-positive individuals, and the con-
verse for the so-called pediatric serotypes in PCV7, has
been shown before [14,15,26,31]. It has been postulated
that HIV-infected adults, like young children, have
reduced immunity to pneumococcal colonization, lead-
ing to increases in disease due to pediatric serotypes that
commonly colonize the nasopharynx [26]. Indeed,
nasopharyngeal colonization among HIV-infected adults
has been shown to be elevated, with rates above 30% in
Kenya and Zambia [34,35]. The high proportion of pneu-
mococci resistant to cotrimoxazole has been shown
before, and likely reflects widespread use of cotrimox-
azole in the community and use of sulfadoxine-
pyrimethamine for malaria treatment in Kenya [35].
Beta-lactam resistance remains low in Kenya and likely
reflects the fact that apart from amoxicillin, few beta-lac-
tam antibiotics are used outside of the inpatient setting.
In Kenya, several large-scale interventions that are
being implemented could lead to a decrease in adult
pneumococcal disease. First, until recently most Kenyans
did not know their HIV status. The 2007 Kenya AIDS
Indicator Survey showed two-thirds of Kenyans did not
know their HIV status and 65% of HIV-infected persons
who needed HAART were not receiving it [22]. However,
HIV testing is now becoming more widespread in Kenya
and HAART is increasingly available for those who need
it due to large multinational funding initiatives. HAART
has been shown to decrease invasive pneumococcal dis-
ease, as well as bacterial pneumonia, in HIV-infected per-
sons [7,36]. Second, Kenya plans to introduce PCV10
(Synflorix™, GlaxoSmithKline, Rixensart, Belgium) for
children in 2010 with support from the Global Alliance
for Vaccines and Immunizations. In the U.S., a large indi-
rect effect of childhood PCV7 (Prevnar™, Wyeth Pharma-
ceuticals, New Jersey, U.S.) vaccination was realized
among adults, with a significant decrease in invasive
pneumococcal disease of 32% among persons 20-39
years, the age group likely to be parents of small children
and also that had the highest rate of pneumococcal bacte-
remia in our study [37]. After PCV7 was introduced in
the U.S., HIV-infected adults showed a 62% decrease in
pneumococcal disease due to vaccine serotypes [38].
PCV10 will include serotype 1, the most common sero-
type among Kenyan adults. Unlike most serotypes
included in PCV7, serotype 1 is not often found in the
nasopharynges of children [32]. Because the indirect
impact of conjugate vaccines work through reduction of
carriage, and thus transmission to other persons, whether
the same degree of herd immunity in Kenyan adults will
be realized for serotype 1 is unclear.
Our study had several limitations. First, we did not have
HIV status on all patients and assuming the same HIV
prevalence among those not tested might have been
incorrect. In particular, patients who died before the
home-based HIV testing initiative began might have been
more likely to be HIV-positive, which would have
resulted in even higher extrapolated rates of pneumococ-
cal bacteremia in HIV-infected persons than we calcu-
lated. Due to the small number of patients with
pneumococcal bacteremia who had HIV testing in our
study, the HIV-specific results should be interpreted with
Table 3: Serotypes of pneumococcal isolates from blood 
culture among persons ≥5 years of age presenting to Lwak 
Hospital, rural western Kenya, October 2006 - September 
2008
Serotype # (%) of total (n = 52a)
1 22 (42)
6B 4 (8)
15A 4 (8)
43  ( 6 )
9V 3 (6)
32  ( 4 )
52  ( 4 )
13 2 (4)
19F 2 (4)
7A 1 (2)
7C 1 (2)
14 1 (2)
20 1 (2)
22F 1 (2)
23A 1 (2)
35B 1 (2)
43 1 (2)
PCV7 serotypesb 13 (25%)
PCV10 serotypesb 37 (71%)
PCV13 serotypesb 39 (75%)
a52 blood cultures yielded 52 serotypes among 51 patients. One 
patient had 6B bacteremia twice in February and August 2007.
bPCV7 includes serotypes 4, 6B, 9V,14, 18C, 19F, 23F. PCV10 adds 
serotypes 1, 5 and 7F. PCV13 adds serotypes 3, 6A, and 19A.Feikin et al. BMC Infectious Diseases 2010, 10:186
http://www.biomedcentral.com/1471-2334/10/186
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Figure 1 Seasonality of pneumococcal bacteremia in rural western Kenya, October 2006 - September 2008. PEV is post-election violence pe-
riod when clinic utilization decreased.
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Table 4: Rates of pneumococcal bacteremia in rural western Kenya, October 2006 - September 2008
Age in 
years
Syndrome S. pneumo (n) Pyoa Rate per 
100,000 Pyo 
(95% CI)
% cultured Rate, 
Extrapolation 1b 
Pyo (95% CI)
% clinic visits 
to Lwak
Rate 
Extrapolation 
2c Pyo (95% CI)
5.17 Overall 11 17917 61 (31-110) -- 160 (65-255) 301 (123-479)
SARI Inpatient 56 4 9 5
SARI Outpatient 44 7 5 4
Admit, not SARI 04 5 9 5
Fever, not SARI 23 8 4 1
18-34 Overall 22 10869 202 (127-306) -- 391 (227-554) 578 (336-820)
SARI Inpatient 10 56 80
SARI Outpatient 86 0 5 1
Admit, not SARI 43 6 7 9
Fever, not SARI 04 0 4 3
35-49 Overall 10 4939 202 (97-372) -- 407 (155-659) 591 (225-957)
SARI Inpatient 56 6 7 7
SARI Outpatient 25 5 5 2
Admit, not SARI 33 4 7 2
Fever, not SARI 06 2 4 2
≥50 Overall 9 6738 134 (61-253) 232 (80-384) 354 (123-585)
SARI Inpatient 77 1 6 7
SARI Outpatient 04 6 4 5
Admit, not SARI 23 5 6 3
Fever, not SARI 04 4 3 8
Overall 52 40463 129 (96-169) 245 (178-312) 419 (305-533)
apyo - person years of observation
bExtrapolation 1 accounts for patients meeting case definitions for blood culture in Lwak clinic who did not have blood cultures done (see methods).
cExtrapolation 2 uses the rates for extrapolation 1 and extrapolates further by accounting for the % of persons at the biweekly home visit with 
SARI or fever who went to a clinic other than Lwak clinic (see methods).Feikin et al. BMC Infectious Diseases 2010, 10:186
http://www.biomedcentral.com/1471-2334/10/186
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some caution. Moreover, our projection of the national
number of pneumococcal bacteremia cases among adults
assumed that no persons ≥65 years old were HIV-posi-
tive, so likely underestimated the true number of cases.
Second, in making extrapolations of bacteremia rates, we
m a d e  s o m e  a s s u m p t i o n s  t h a t  c o u l d  h a v e  b i a s e d  o u r
adjusted rates. We assumed isolation rates would be the
same among those with the same syndromes who did not
get blood cultures. At Lwak, cultures might have been
performed more frequently among patients more likely to
have pneumococcal bacteremia (e.g. sicker patients).
Also, persons in the community might have been more
likely to go to Lwak than other clinics if they were sicker,
knowing that admission was free at Lwak. Third, we only
cultured the blood of the first two febrile adults, which
possibly could have led to a systematic bias if the first two
patients were more or less likely to have bacteremia than
other febrile patients. Moreover, by culturing the major-
ity of SARI patients, while only a sample of febrile
patients, we likely biased our results towards finding
more pneumococcus and less mycobacteria and non-
typhi salmonellae, which have also been shown to be
prevalent, sometimes more so than pneumococcus,
among febrile, HIV-infected persons admitted to hospital
[4,9-11]. Lastly, because we did not do lumbar punctures,
our analysis did not include pneumococcal meningitis,
the other major manifestation of invasive pneumococcal
disease.
Conclusions
We showed a high burden of pneumococcal bacteremia
in older children and adults in western Kenya. As shown
before, that burden is exacerbated by the HIV epidemic in
Africa. Further surveillance is needed to assess the
impact of potential preventive strategies, such as expand-
ing HAART among HIV-infected persons and the indi-
rect effect of the introduction of pneumococcal conjugate
vaccines in children, and to decide whether additional
targeted interventions, such as adult vaccination with
pneumococcal conjugate vaccine, might be needed to
alleviate the great burden of pneumococcal disease
among older children and adults in Africa [39]. Lastly, in
light of the high rate of bacteremia that we and others
found in adults in parts of Africa with high HIV preva-
lence, more widespread provision of microbiology ser-
vices in clinical settings could result in improved patient
care.
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